title: Idiopathic pyoderma gangrenosum: successful resolution with infliximab therapy and pro-inflammatory cytokines assessment.
authors.affiliation: Allergy & Clinical Immunology Unit, University of Cagliari, University Hospital, Asse Didattico E1, IT-09042 Monserrato Cagliari, Italy. stedg@medicina.unica.it
authors.forename: Stefano R
authors.initials: SR
authors.lastname: Del Giacco
authors.forename: Davide
authors.initials: D
authors.lastname: Firinu
authors.forename: Maria Maddalena
authors.initials: MM
authors.lastname: Lorrai
authors.forename: Loredana
authors.initials: L
authors.lastname: Serusi
authors.forename: Raffaella
authors.initials: R
authors.lastname: Meleddu
authors.forename: Maria Pina
authors.initials: MP
authors.lastname: Barca
authors.forename: Monica
authors.initials: M
authors.lastname: Peralta
authors.forename: Paolo Emilio
authors.initials: PE
authors.lastname: Manconi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001706:Biopsy; D016207:Cytokines / Q000097:blood*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D000069285:Infliximab; D055985:Latent Tuberculosis / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000995:Antitubercular Agents; D016207:Cytokines; D003879:Dermatologic Agents; D005938:Glucocorticoids; D018836:Inflammation Mediators; D000069285:Infliximab; D011241:Prednisone